Celcuity submits sNDA to FDA for REVTORPYK in HR+/HER2-, PIK3CA-mutant breast cancer
Celcuity submitted an sNDA to the FDA for REVTORPYK (gedatolisib) for HR+/HER2-, PIK3CA-mutant locally advanced or metastatic breast cancer.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.